Background Percutaneous ablation is a common treatment for colorectal liver metastases (CLM). However, the effect of RAS mutation on outcome after ablation of CLMs is unclear. Methods Patients who underwent image-guided percutaneous ablation of CLMs from 2004 through 2015 and had known Rat sarcoma viral oncogene homolog (RAS mutation status were analyzed. Patients were evaluated for local tumor progression as observed on imaging at CLM treated with ablation. Multivariable Cox regression analysis was performed to determine factors associated with local tumour progression-free survival. Results The study included 92 patients who underwent ablation of 137 CLMs. Thirty-six patients (39%) had mutant RAS. Rates of local tumour progression were 14% (8/56) for patients with wild-type RAS and 39% (14/36) for patients with mutant RAS (p=0·007). Actuarial local tumour progression-free survival after percutaneous ablation were worse in patients with mutant RAS than wild-type RAS (3-year local tumour progression-free survival rate: 35% vs. 71%, p=0.001). In multivariable analysis, negative predictors of local tumour progression-free survival were minimal ablation margin <5 mm (hazard ratio [HR] 2·48, 95% confidence interval [CI] 1·31–4·72; p=0·006) and mutant RAS (HR 3·01, 95% CI 1·60–5·77; p=0·001). Conclusion Mutant RAS is associated with an earlier and higher rate of local tumour progression in patients undergoing ablation of CLM.

No abstract

No abstract

MRE is a reliable noninvasive technique to measure LS in a swine model of cirrhosis. Significant positive correlations were observed between LS and HVPG as well as LS and fibrosis.

No abstract